Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$65 Mln
P/E Ratio
--
P/B Ratio
8.59
Industry P/E
--
Debt to Equity
1.05
ROE
-1.8 %
ROCE
-71.42 %
Div. Yield
0 %
Book Value
0.16
EPS
-1.13
CFO
$-161.08 Mln
EBITDA
$-157.84 Mln
Net Profit
$-208.36 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Akoya BioSciences (AKYA)
| -47.16 | -15.38 | -59.67 | -68.65 | -49.53 | -- | -- |
|
BSE Sensex
| 2.55 | 3.65 | 4.54 | 7.46 | 12.04 | 19.65 | 11.41 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Akoya BioSciences (AKYA)
| -52.78 | -49.01 | -37.49 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 12.89 | 10,202.62 | 12.01 | 12.69 | |
| 70.96 | 10,025.34 | 96.83 | 2.52 | |
| 288.68 | 11,513.99 | 277.87 | 3.65 | |
| 117.67 | 14,455.82 | 41.45 | 5.44 |
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions for transforming discovery, clinical research, and diagnostics in North America, the Asia-Pacific, Europe, the Middle East, and Africa. The company offers... PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. Akoya Biosciences, Inc. was incorporated in 2015 and is headquartered in Marlborough, Massachusetts. Address: 100 Campus Drive, Marlborough, MA, United States, 01752 Read more
President, CEO & Director
Mr. Brian McKelligon
President, CEO & Director
Mr. Brian McKelligon
Headquarters
Marlborough, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Akoya BioSciences Inc (AKYA) stood at $ 125 Mln as on 31-Dec-24
The share price of Akoya BioSciences Inc (AKYA) is $1.21 (NASDAQ) as of 30-Apr-2025 15:44 EDT. Akoya BioSciences Inc (AKYA) has given a return of -49.53% in the last 3 years.
Akoya BioSciences Inc (AKYA) has a market capitalisation of $ 65 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Akoya BioSciences Inc (AKYA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Akoya BioSciences Inc (AKYA) and enter the required number of quantities and click on buy to purchase the shares of Akoya BioSciences Inc (AKYA).
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions for transforming discovery, clinical research, and diagnostics in North America, the Asia-Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. Akoya Biosciences, Inc. was incorporated in 2015 and is headquartered in Marlborough, Massachusetts. Address: 100 Campus Drive, Marlborough, MA, United States, 01752
The CEO & director of Mr. Brian McKelligon. is Akoya BioSciences Inc (AKYA), and CFO & Sr. VP is Mr. Brian McKelligon.
There is no promoter pledging in Akoya BioSciences Inc (AKYA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,126
|
|
|
1,078
|
|
|
1,054
|
|
|
964
|
| Akoya BioSciences Inc. (AKYA) | Ratios |
|---|---|
|
Return on equity(%)
|
-180.44
|
|
Operating margin(%)
|
-54.84
|
|
Net Margin(%)
|
-67.79
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Akoya BioSciences Inc (AKYA) was $0 Mln.
$-0.06
(
